Academic Journal
The cholesterol-lowering effect of unripe Rubus coreanus is associated with decreased oxidized LDL and apolipoprotein B levels in subjects with borderline-high cholesterol levels: a randomized controlled trial
| العنوان: | The cholesterol-lowering effect of unripe Rubus coreanus is associated with decreased oxidized LDL and apolipoprotein B levels in subjects with borderline-high cholesterol levels: a randomized controlled trial |
|---|---|
| المؤلفون: | Cho, Jung Min, Chae, Jisuk, Jeong, Sa Rang, Moon, Min Jung, Ha, Ki-Chan, Kim, Sunoh, Lee, Jong Ho |
| المساهمون: | Korea Institute of Planning & Evaluation for Technology in Food, Agriculture Forestry & Fisheries |
| المصدر: | Lipids in Health and Disease ; volume 19, issue 1 ; ISSN 1476-511X |
| بيانات النشر: | Springer Science and Business Media LLC |
| سنة النشر: | 2020 |
| الوصف: | Background Rubus coreanus ( R. coreanus ) possesses properties that may decrease cholesterol levels. Methods The effects of unripe R. coreanus (uRC) consumption on low-density lipoprotein (LDL) and total cholesterol levels related to decreased circulating apolipoprotein (Apo) B and oxidized LDL levels were evaluated. This randomized, double-blind, placebo-controlled study included subjects with borderline-high cholesterol levels (between 200 and 239 mg/dL) who consumed one capsule daily containing 600 mg of freeze-dried uRC extract ( n = 39) or the placebo ( n = 38). Results After 12 weeks, the uRC group showed reductions of 21.23 ± 4.36 mg/dL in total cholesterol levels ( P = 0.007) and 15.61 ± 4.16 mg/dL in LDL cholesterol levels ( P = 0.032). In addition, significantly greater reductions in Apo B levels were observed in the uRC group (− 3.48 ± 3.40 mg/dL), but Apo B levels were increased in the placebo group (6.21 ± 2.84 mg/dL; P = 0.032). Furthermore, a remarkably lower oxidized LDL level was detected in the uRC group (57.76 ± 2.07 U/L) than in the placebo group (66.09 ± 3.47 U/L) after 12 weeks of consumption ( P = 0.044). Conclusions Because of its cholesterol-lowering effect, uRC shows great promise as a therapeutic agent for subjects with borderline-high total blood cholesterol levels. Trial registration ClinicalTrials.gov Identifier: NCT03649620 (8/28/2018, retrospectively registered). |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1186/s12944-020-01338-z |
| DOI: | 10.1186/s12944-020-01338-z.pdf |
| DOI: | 10.1186/s12944-020-01338-z/fulltext.html |
| الاتاحة: | http://dx.doi.org/10.1186/s12944-020-01338-z https://link.springer.com/content/pdf/10.1186/s12944-020-01338-z.pdf https://link.springer.com/article/10.1186/s12944-020-01338-z/fulltext.html |
| Rights: | https://creativecommons.org/licenses/by/4.0 ; https://creativecommons.org/licenses/by/4.0 |
| رقم الانضمام: | edsbas.9CA2879A |
| قاعدة البيانات: | BASE |
| DOI: | 10.1186/s12944-020-01338-z |
|---|